BHVN•benzinga•
Biohaven Highlights Phase 1 Data For BHV-1400 In IgA Nephropathy With 70% Reduction In Target Antibody. Advances Include BHV-1600 For PPCM And BHV-1300 For Graves' Disease. Multiple Trials Set For 2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 13, 2025 by benzinga